Back to Search
Start Over
A genetically engineered, stem-cell-derived cellular vaccine
- Source :
- Cell Reports Medicine. 3:100843
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- Despite rapid clinical translation of COVID-19 vaccines in response to the global pandemic, an opportunity remains for vaccine technology innovation to address current limitations and meet challenges of inevitable future pandemics. We describe a universal vaccine cell (UVC) genetically engineered to mimic natural physiological immunity induced upon viral infection of host cells. Cells engineered to express the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike as a representative viral antigen induce robust neutralizing antibodies in immunized non-human primates. Similar titers generated in this established non-human primate (NHP) model have translated into protective human neutralizing antibody levels in SARS-CoV-2-vaccinated individuals. Animals vaccinated with ancestral spike antigens and subsequently challenged with SARS-CoV-2 Delta variant in a heterologous challenge have an approximately 3 log decrease in viral subgenomic RNA in the lungs. This cellular vaccine is designed as a scalable cell line with a modular poly-antigenic payload, allowing for rapid, large-scale clinical manufacturing and use in an evolving viral variant environment.
Details
- ISSN :
- 26663791
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Cell Reports Medicine
- Accession number :
- edsair.doi.dedup.....9d15e248db6af8c4c213f0073d859e6c